Zinc Sulfate for Human Papillomavirus (HPV)
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 21 - 65 |
| Updated: | 1/21/2018 |
| Start Date: | October 24, 2017 |
| End Date: | December 31, 2018 |
| Contact: | Nicole A Walker, BS |
| Email: | nicole.walker@spectrumhealth.org |
| Phone: | 616-486-6332 |
Oral Zinc Sulfate for the Treatment of High Risk Cervical HPV Versus Placebo
The Human Papillomavirus (HPV) is well established as the primary causative agent in both
warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high
rate of spontaneous resolution this takes time and the infection can cause cervical cells to
progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in
immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high
risk HPV versus placebo.
warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high
rate of spontaneous resolution this takes time and the infection can cause cervical cells to
progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in
immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high
risk HPV versus placebo.
Upon enrollment eligible participants will be randomized and given a three-month supply of
zinc sulfate or placebo to be taken as directed. They will have zinc serum lab testing at
enrollment and upon study completion. Patients will also be asked to complete short
questionnaires and to make study staff aware of any side effects they should experience.
zinc sulfate or placebo to be taken as directed. They will have zinc serum lab testing at
enrollment and upon study completion. Patients will also be asked to complete short
questionnaires and to make study staff aware of any side effects they should experience.
Inclusion Criteria:
- Abnormal cytology of atypical squamous cells of undetermined significance (ASCUS) on
Pap smear OR
- Low-grade squamous intra epithelial lesions (LSIL) on Pap smear OR
- Positive hrHPV on routine screening (positive HPV will be assumed to be high grade)
Exclusion Criteria:
- Patients who proceed to excisional procedures (loop electrosurgical excision procedure
or cold knife conization)
- Pregnant patients
- Breastfeeding patients
- Immunocompromised patients
We found this trial at
1
site
Grand Rapids, Michigan 49503
Principal Investigator: Rebecca Prudnick, DO
Phone: 616-486-6332
Click here to add this to my saved trials
